![]() |
|
|
Vol. 294, Issue 3, 963-968, September 2000
Medizinische Poliklinik, Experimentelle Nephrologie,
Westfälische Wilhelms-Universität, Münster, Germany
Diadenosine polyphosphates (ApnA; n = 3-6) are
potent vasoactive agents in isolated vessels. Information on effects of
ApnA in vivo is still limited despite the fact that these compounds are
starting to be used in humans. This study was designed to compare the
effects of ApnA and their possible metabolites on blood pressure in
vivo and to functionally identify purinoceptors involved in their
action. All four ApnA and their degradation products induced a
sustained drop of mean arterial blood pressure during i.v.
infusion, which was fully reversible. The rank order of potency was
Ap4A
Ap6A > Ap5A = Ap3A = ATP = ADP > AMP
adenosine, suggesting that the hypotensive effect is
predominantly evoked by the original dinucleotides and not by their
degradation products. The hypotensive effect of Ap5A was reduced by the
P2X and P2Y1 purinoceptor antagonist
pyridoxal-phosphate-6-azophenyl-2',4'-disulfonic acid, the
A1 purinoceptor antagonist
8-cyclopentyl-1,3-dipropylxanthine, and the A2 purinoceptor
antagonist 3,7-dimethyl-1-propargylxanthine. The hypertensive effect by
the prototype P2X receptor agonist 
-methylene ATP was inhibited
by pyridoxal-phosphate-6-azophenyl-2',4'-disulfonic acid, too.
Purinoceptor antagonists reduced the maximal effects of the agonists
indicating a noncompetitive inhibition. In summary, the reported
vasocontractile effect of ApnA seems to be limited to isolated
preparations under resting tone conditions; however, the systemic
cardiovascular effects of all four ApnA are hypotensive, also making
them candidates for blood pressure reduction in humans. These effects
are fast in onset and easily reversible. Activation of different
purinoceptors in the vasculature (most probably P2Y1 and
A2 receptors) contributes to the Ap5A-induced decrease of mean arterial blood pressure.
This article has been cited by other articles:
![]() |
G. Gabriels, K. H. Rahn, E. Schlatter, and M. Steinmetz Mesenteric and renal vascular effects of diadenosine polyphosphates (APnA) Cardiovasc Res, October 1, 2002; 56(1): 22 - 32. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Steinmetz, A.-K. Janssen, F. Pelster, K. H. Rahn, and E. Schlatter Vasoactivity of Diadenosine Polyphosphates in Human Small Mesenteric Resistance Arteries J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 787 - 794. [Abstract] [Full Text] [PDF] |
||||